Eve review
Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
Est. first month
From $195/mo (compounded)
- Semaglutide
- From $195/mo (compounded)
- Tirzepatide
- From $195/mo (compounded)
- Coverage
- Coverage not published
- Brand-name
- Yes
The Value Score card
Eve scored on our six published factors. See the methodology.
Why it's a deal
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Read the fine print
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
The bottom line
Best for: Shoppers who want women's-health GLP-1 with compounded or brand-name access. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
Ranked #333 of 395 programs we track — see our #1 deal, CoreAge Rx, for comparison.
Compare with other deals
The programs scoring closest to Eve, out of 394 others we track.
Shopping Eve against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs Eve, and every program that undercuts or outscores it is ranked on the Eve alternatives board.
- From $187/mo (compounded)Whoosh Wellness— Whoosh Wellness is a physician-guided GLP-1 and peptide telehealth service offering compounded semaglutide (from $187/mo) and tirzepatide (from $235/mo), with everything bundled into one price — physician…64/100
- From $199/mo (plus a separate fee, compounded)Concierge MD LA— Concierge MD LA offers semaglutide ($199/mo) and tirzepatide ($299/mo) alongside brand-name Ozempic, Mounjaro, Zepbound, and Wegovy ($1,999/mo each).63/100
- From $249/mo (compounded)Elara MD— Elara MD is a weight-loss and wellness telehealth platform offering weekly injectable GLP-1 therapy alongside a peptide menu (NAD+, sermorelin, glutathione).63/100
- From $199/mo (starting dose, plus a separate fee, compounded)Lumora— Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.63/100
- From $162/mo (compounded)Medivive— Medivive is a US telehealth service offering compounded semaglutide and tirzepatide for weight loss, filled through a licensed pharmacy, with providers licensed in all 50 states and no insurance required.63/100
- From $99/mo (compounded)Noom Med— Noom Med integrates GLP-1 medication access with Noom's proven cognitive behavioral therapy curriculum, 1-on-1 dietitian coaching, and dedicated care team — the most comprehensive psychology-plus-medication…63/100
More programs we track (24)
- #1 CoreAge Rx93
- #2 Ondra Health92
- #4 Vitara RX91
- #5 Gimme Care91
- #7 Alan Meds90
- #3 Trimi Health89
- #10 Precision Telemed89
- #11 bmiMD89
- #12 Care Clinics89
- #6 Oak88
- #16 Live Vital88
- #17 AmberHealth88
- #18 Fresh Day Meds88
- #8 Sesame Care87
- #9 Strut Health87
- #22 EverSlim87
- #23 NewSelf87
- #24 Vaylen87
- #25 Mint Med87
- #13 HealthRX86
- #14 RxSpan MD86
- #15 Sprout Health86
- #28 Bionomy Health86
- #29 BetterMe Rx86
364 more are reviewed too — see every GLP-1 program we track, ranked.
Pricing and coverage on this page were read from Eve's own website on ; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on Eve's site. Not medical advice; see our disclosure.